This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
This document provides laboratories with a single protocol for producing recombinant full-length hamster prion protein and using it to perform the Real-Time Quaking-Induced Conversion assay (RT-QuIC), which can distinguish sporadic Creutzfeldt-Jakob disease (sCJD) from variant Creutzfeldt-Jakob disease (vCJD).
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.